Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice

Morales, José María García Ruiz de; Pascual‐Salcedo, Dora; Tello, Francisca Llinares; Valor‐Méndez, Larissa

doi:10.1016/j.medcle.2016.11.019

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteoarthritis (OA) is the most common musculoskeletal disease in the world, and can lead to increasing disability. 57 There are currently no effective drugs to treat OA or to protect joints from degeneration. 58 Since OA has a significant impact on a patient's health and quality of life, the prevention and treatment of OA are urgently needed.…”

Section: Application Of Ms-based Metabolomics In Medical Sciencementioning

confidence: 99%

Mass spectrometry-based metabolomics in health and medical science: a systematic review

Zhang

et al. 2020

RSC Adv.

141

View full text Add to dashboard Cite

show abstract

Section: Application Of Ms-based Metabolomics In Medical Sciencementioning

confidence: 99%

Mass spectrometry-based metabolomics in health and medical science: a systematic review

Zhang

et al. 2020

RSC Adv.

141

View full text Add to dashboard Cite

show abstract

Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review

et al. 2018

View full text Add to dashboard Cite

The utility of monitoring drug levels in rheumatoid arthritis and spondyloarthritis patients on biological therapy is called into question. The objective was to study relevant clinical questions on the topic, i.e., (1) whether drug levels predict relapse in patients whose biologic was optimized because of remission or low disease activity; (2) whether information about drug levels influences the prognosis of patients with primary or secondary failure to a biological therapy; and (3) whether methotrexate (MTX) influences the association between drug levels and response. Medline, Embase, Cochrane databases were screened, from inception to December 2016 in search for all studies related to the three research questions about. Overall characteristics and outcomes of the studies were collected in a table of evidence and the quality of the studies was assessed with the Newcastle-Ottawa scale or the GRADEpro. Two studies responded the first question, 5 the second, and 7 the third. Studies were small and with limitations, but suggest that measurement drug levels may be useful in patients in remission; that higher drug levels predict a longer relapse-free optimization, and in patients with failure to a biological agent, treatment may need individual adjustment according to the presence of drug levels or antidrug-antibodies. In addition, MTX influences the association between response and drug levels. Monitoring drug levels would allow optimal use of current biological therapies, but more studies and of better quality are needed to draw definitive conclusions.

show abstract

Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis

Rosas

Martín-López

Otón

et al. 2020

Reumatología Clínica (English Edition)

View full text Add to dashboard Cite

Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice

Cited by 3 publications

References 30 publications

Mass spectrometry-based metabolomics in health and medical science: a systematic review

Mass spectrometry-based metabolomics in health and medical science: a systematic review

Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review

Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis

Contact Info

Product

Resources

About